A new antibody‑drug conjugate, M‑3554, targeting GD2 showed robust antitumor activity in neuroblastoma and soft tissue sarcoma models (168c1410c7e7c25f). The ADC uses a β‑glucuronide cleavable linker and exatecan payload and was engineered to reduce pain associated with anti‑GD2 antibodies. Key result: M‑3554 produced strong tumor regressions in xenograft studies while attempting to mitigate off‑target pain signals historically linked to GD2 targeting. The investigators highlight linker stability and payload potency as drivers of the compound’s efficacy. The study positions M‑3554 as a candidate for development in GD2‑expressing pediatric and adult solid tumors; developers and investors should note the continued momentum for next‑generation ADCs that combine improved payload chemistry with tolerability engineering.